市場調査レポート
商品コード
1410698

認知症・運動障害治療の世界市場 2024-2028

Global Dementia and Movement Disorder Treatment Market 2024-2028

出版日: | 発行: TechNavio | ページ情報: 英文 177 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
認知症・運動障害治療の世界市場 2024-2028
出版日: 2024年01月05日
発行: TechNavio
ページ情報: 英文 177 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

認知症・運動障害治療市場は2023-2028年に85億5,000万米ドル、予測期間中のCAGRは7.28%で成長すると予測されます。

当レポートでは、認知症・運動障害治療市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、高齢者人口の増加、対象疾患の有病率の上昇、社会的認知度を高める戦略の出現などによって牽引されています。

市場範囲
基準年 2024
終了年 2028
予測期間 2024-2028
成長モメンタム 加速
前年比2024年 6.63%
CAGR 7.28%
増分額 85億5,000万米ドル

本調査では、今後数年間の認知症・運動障害治療の市場成長を牽引する主要因の1つとして、バイオマーカーの出現を挙げています。また、アルツハイマー病に伴う認知機能低下を回復させる遺伝子治療の成長と生物医学の進歩は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2023
  • 市場の見通し 2023-2028

第4章 市場規模実績

  • 認知症・運動障害治療の世界市場 2018-2022
  • 用途別セグメント分析 2018-2022
  • 薬物クラスセグメント分析 2018-2022
  • 地域別セグメント分析 2018-2022
  • 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:用途別

  • 市場セグメント
  • 比較:用途別
  • 運動障害:市場規模と予測 2023-2028
  • 進行性認知症:市場規模と予測 2023-2028
  • 神経学的異常を伴う進行性認知症(PDNA):市場規模と予測 2023-2028
  • 市場機会:用途別

第7章 市場セグメンテーション薬剤クラス別

  • 市場セグメント
  • 比較薬剤クラス別
  • MAO阻害剤:市場規模と予測 2023-2028
  • アセチルコリンエステラーゼ阻害剤:市場規模と予測 2023-2028
  • グルタミン酸阻害剤:市場規模と予測 2023-2028
  • その他:市場規模と予測 2023-2028
  • 市場機会薬剤クラス別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2023-2028
  • 欧州:市場規模と予測 2023-2028
  • アジア:市場規模と予測 2023-2028
  • 世界のその他の地域:市場規模と予測 2023-2028
  • 米国:市場規模と予測 2023-2028
  • ドイツ:市場規模と予測 2023-2028
  • 英国:市場規模と予測 2023-2028
  • カナダ:市場規模と予測 2023-2028
  • フランス:市場規模と予測 2023-2028
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Amneal Pharmaceuticals Inc.
  • Biogen Inc.
  • Eisai Co. Ltd.
  • H Lundbeck AS
  • Johnson and Johnson
  • Kirin Holdings Co. Ltd.
  • Lannett Co. Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Application
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Historic Market Size - Data Table on global dementia and movement disorder treatment market 2018 - 2022 ($ billion)
  • Exhibits19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
  • Exhibits20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
  • Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
  • Exhibits23: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits29: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits30: Chart on Application - Market share 2023-2028 (%)
  • Exhibits31: Data Table on Application - Market share 2023-2028 (%)
  • Exhibits32: Chart on Comparison by Application
  • Exhibits33: Data Table on Comparison by Application
  • Exhibits34: Chart on Movement disorders - Market size and forecast 2023-2028 ($ billion)
  • Exhibits35: Data Table on Movement disorders - Market size and forecast 2023-2028 ($ billion)
  • Exhibits36: Chart on Movement disorders - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Data Table on Movement disorders - Year-over-year growth 2023-2028 (%)
  • Exhibits38: Chart on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits39: Data Table on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits40: Chart on Progressive dementia - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Data Table on Progressive dementia - Year-over-year growth 2023-2028 (%)
  • Exhibits42: Chart on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits43: Data Table on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits44: Chart on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
  • Exhibits45: Data Table on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
  • Exhibits46: Market opportunity by Application ($ billion)
  • Exhibits47: Data Table on Market opportunity by Application ($ billion)
  • Exhibits48: Chart on Drug Class - Market share 2023-2028 (%)
  • Exhibits49: Data Table on Drug Class - Market share 2023-2028 (%)
  • Exhibits50: Chart on Comparison by Drug Class
  • Exhibits51: Data Table on Comparison by Drug Class
  • Exhibits52: Chart on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits53: Data Table on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits54: Chart on MAO inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits55: Data Table on MAO inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits56: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits57: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits58: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Chart on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits61: Data Table on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibits62: Chart on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits63: Data Table on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibits64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibits65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibits66: Chart on Others - Year-over-year growth 2023-2028 (%)
  • Exhibits67: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • Exhibits68: Market opportunity by Drug Class ($ billion)
  • Exhibits69: Data Table on Market opportunity by Drug Class ($ billion)
  • Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits73: Chart on Geographic comparison
  • Exhibits74: Data Table on Geographic comparison
  • Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%)
  • Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibits104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibits105: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits107: Chart on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibits108: Data Table on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibits109: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibits110: Data Table on France - Year-over-year growth 2023-2028 (%)
  • Exhibits111: Market opportunity By Geographical Landscape ($ billion)
  • Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
  • Exhibits113: Impact of drivers and challenges in 2023 and 2028
  • Exhibits114: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits115: Overview on factors of disruption
  • Exhibits116: Impact of key risks on business
  • Exhibits117: Vendors covered
  • Exhibits118: Matrix on vendor position and classification
  • Exhibits119: AbbVie Inc. - Overview
  • Exhibits120: AbbVie Inc. - Product / Service
  • Exhibits121: AbbVie Inc. - Key news
  • Exhibits122: AbbVie Inc. - Key offerings
  • Exhibits123: Acorda Therapeutics Inc. - Overview
  • Exhibits124: Acorda Therapeutics Inc. - Product / Service
  • Exhibits125: Acorda Therapeutics Inc. - Key offerings
  • Exhibits126: Amneal Pharmaceuticals Inc. - Overview
  • Exhibits127: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibits128: Amneal Pharmaceuticals Inc. - Key news
  • Exhibits129: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibits130: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibits131: Biogen Inc. - Overview
  • Exhibits132: Biogen Inc. - Product / Service
  • Exhibits133: Biogen Inc. - Key offerings
  • Exhibits134: Eisai Co. Ltd. - Overview
  • Exhibits135: Eisai Co. Ltd. - Business segments
  • Exhibits136: Eisai Co. Ltd. - Key offerings
  • Exhibits137: Eisai Co. Ltd. - Segment focus
  • Exhibits138: H Lundbeck AS - Overview
  • Exhibits139: H Lundbeck AS - Product / Service
  • Exhibits140: H Lundbeck AS - Key offerings
  • Exhibits141: Johnson and Johnson - Overview
  • Exhibits142: Johnson and Johnson - Business segments
  • Exhibits143: Johnson and Johnson - Key news
  • Exhibits144: Johnson and Johnson - Key offerings
  • Exhibits145: Johnson and Johnson - Segment focus
  • Exhibits146: Kirin Holdings Co. Ltd. - Overview
  • Exhibits147: Kirin Holdings Co. Ltd. - Business segments
  • Exhibits148: Kirin Holdings Co. Ltd. - Key offerings
  • Exhibits149: Kirin Holdings Co. Ltd. - Segment focus
  • Exhibits150: Lannett Co. Inc. - Overview
  • Exhibits151: Lannett Co. Inc. - Product / Service
  • Exhibits152: Lannett Co. Inc. - Key offerings
  • Exhibits153: Merck and Co. Inc. - Overview
  • Exhibits154: Merck and Co. Inc. - Business segments
  • Exhibits155: Merck and Co. Inc. - Key news
  • Exhibits156: Merck and Co. Inc. - Key offerings
  • Exhibits157: Merck and Co. Inc. - Segment focus
  • Exhibits158: Novartis AG - Overview
  • Exhibits159: Novartis AG - Business segments
  • Exhibits160: Novartis AG - Key offerings
  • Exhibits161: Novartis AG - Segment focus
  • Exhibits162: Otsuka Holdings Co. Ltd. - Overview
  • Exhibits163: Otsuka Holdings Co. Ltd. - Business segments
  • Exhibits164: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibits165: Otsuka Holdings Co. Ltd. - Segment focus
  • Exhibits166: Supernus Pharmaceuticals Inc. - Overview
  • Exhibits167: Supernus Pharmaceuticals Inc. - Product / Service
  • Exhibits168: Supernus Pharmaceuticals Inc. - Key offerings
  • Exhibits169: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits170: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits171: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits172: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits173: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits174: UCB SA - Overview
  • Exhibits175: UCB SA - Product / Service
  • Exhibits176: UCB SA - Key offerings
  • Exhibits177: Inclusions checklist
  • Exhibits178: Exclusions checklist
  • Exhibits179: Currency conversion rates for US$
  • Exhibits180: Research methodology
  • Exhibits181: Validation techniques employed for market sizing
  • Exhibits182: Information sources
  • Exhibits183: List of abbreviations
目次
Product Code: IRTNTR73379

Abstract

The dementia and movement disorder treatment market is forecasted to grow by USD 8.55 bn during 2023-2028, accelerating at a CAGR of 7.28% during the forecast period. The report on the dementia and movement disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, rising prevalence of target diseases, and emergence of strategies to increase public awareness.

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20246.63%
CAGR7.28%
Incremental Value$8.55bn

Technavio's dementia and movement disorder treatment market is segmented as below:

By Application

  • Movement disorders
  • Progressive dementia
  • Progressive dementia with neurological abnormality (PDNA)

By Drug Class

  • MAO inhibitors
  • Acetylcholinesterase inhibitors
  • Glutamate inhibitors
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the emergence of biomarkers as one of the prime reasons driving the dementia and movement disorder treatment market growth during the next few years. Also, growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease and advances in biomedical science will lead to sizable demand in the market.

The report on the dementia and movement disorder treatment market covers the following areas:

  • Dementia and movement disorder treatment market sizing
  • Dementia and movement disorder treatment market forecast
  • Dementia and movement disorder treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dementia and movement disorder treatment market vendors that include AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the dementia and movement disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global dementia and movement disorder treatment market 2018 - 2022
  • Exhibit 18: Historic Market Size - Data Table on global dementia and movement disorder treatment market 2018 - 2022 ($ billion)
  • 4.2 Application Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
  • 4.3 Drug Class Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
  • 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
  • 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

  • 6.1 Market segments
  • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
  • 6.2 Comparison by Application
  • Exhibit 32: Chart on Comparison by Application
  • Exhibit 33: Data Table on Comparison by Application
  • 6.3 Movement disorders - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Movement disorders - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 35: Data Table on Movement disorders - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 36: Chart on Movement disorders - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Movement disorders - Year-over-year growth 2023-2028 (%)
  • 6.4 Progressive dementia - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 39: Data Table on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 40: Chart on Progressive dementia - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Progressive dementia - Year-over-year growth 2023-2028 (%)
  • 6.5 Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028
  • Exhibit 42: Chart on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 43: Data Table on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 44: Chart on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
  • Exhibit 45: Data Table on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
  • 6.6 Market opportunity by Application
  • Exhibit 46: Market opportunity by Application ($ billion)
  • Exhibit 47: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Drug Class

  • 7.1 Market segments
  • Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
  • Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
  • 7.2 Comparison by Drug Class
  • Exhibit 50: Chart on Comparison by Drug Class
  • Exhibit 51: Data Table on Comparison by Drug Class
  • 7.3 MAO inhibitors - Market size and forecast 2023-2028
  • Exhibit 52: Chart on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 53: Data Table on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 54: Chart on MAO inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on MAO inhibitors - Year-over-year growth 2023-2028 (%)
  • 7.4 Acetylcholinesterase inhibitors - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 57: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 58: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
  • 7.5 Glutamate inhibitors - Market size and forecast 2023-2028
  • Exhibit 60: Chart on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 61: Data Table on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 62: Chart on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
  • Exhibit 63: Data Table on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
  • 7.6 Others - Market size and forecast 2023-2028
  • Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
  • Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 7.7 Market opportunity by Drug Class
  • Exhibit 68: Market opportunity by Drug Class ($ billion)
  • Exhibit 69: Data Table on Market opportunity by Drug Class ($ billion)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • 9.2 Geographic comparison
  • Exhibit 73: Chart on Geographic comparison
  • Exhibit 74: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
  • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 Germany - Market size and forecast 2023-2028
  • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.9 UK - Market size and forecast 2023-2028
  • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 9.10 Canada - Market size and forecast 2023-2028
  • Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • 9.11 France - Market size and forecast 2023-2028
  • Exhibit 107: Chart on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 108: Data Table on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 109: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibit 110: Data Table on France - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
  • Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 115: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 116: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 117: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 118: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 119: AbbVie Inc. - Overview
  • Exhibit 120: AbbVie Inc. - Product / Service
  • Exhibit 121: AbbVie Inc. - Key news
  • Exhibit 122: AbbVie Inc. - Key offerings
  • 12.4 Acorda Therapeutics Inc.
  • Exhibit 123: Acorda Therapeutics Inc. - Overview
  • Exhibit 124: Acorda Therapeutics Inc. - Product / Service
  • Exhibit 125: Acorda Therapeutics Inc. - Key offerings
  • 12.5 Amneal Pharmaceuticals Inc.
  • Exhibit 126: Amneal Pharmaceuticals Inc. - Overview
  • Exhibit 127: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 128: Amneal Pharmaceuticals Inc. - Key news
  • Exhibit 129: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 130: Amneal Pharmaceuticals Inc. - Segment focus
  • 12.6 Biogen Inc.
  • Exhibit 131: Biogen Inc. - Overview
  • Exhibit 132: Biogen Inc. - Product / Service
  • Exhibit 133: Biogen Inc. - Key offerings
  • 12.7 Eisai Co. Ltd.
  • Exhibit 134: Eisai Co. Ltd. - Overview
  • Exhibit 135: Eisai Co. Ltd. - Business segments
  • Exhibit 136: Eisai Co. Ltd. - Key offerings
  • Exhibit 137: Eisai Co. Ltd. - Segment focus
  • 12.8 H Lundbeck AS
  • Exhibit 138: H Lundbeck AS - Overview
  • Exhibit 139: H Lundbeck AS - Product / Service
  • Exhibit 140: H Lundbeck AS - Key offerings
  • 12.9 Johnson and Johnson
  • Exhibit 141: Johnson and Johnson - Overview
  • Exhibit 142: Johnson and Johnson - Business segments
  • Exhibit 143: Johnson and Johnson - Key news
  • Exhibit 144: Johnson and Johnson - Key offerings
  • Exhibit 145: Johnson and Johnson - Segment focus
  • 12.10 Kirin Holdings Co. Ltd.
  • Exhibit 146: Kirin Holdings Co. Ltd. - Overview
  • Exhibit 147: Kirin Holdings Co. Ltd. - Business segments
  • Exhibit 148: Kirin Holdings Co. Ltd. - Key offerings
  • Exhibit 149: Kirin Holdings Co. Ltd. - Segment focus
  • 12.11 Lannett Co. Inc.
  • Exhibit 150: Lannett Co. Inc. - Overview
  • Exhibit 151: Lannett Co. Inc. - Product / Service
  • Exhibit 152: Lannett Co. Inc. - Key offerings
  • 12.12 Merck and Co. Inc.
  • Exhibit 153: Merck and Co. Inc. - Overview
  • Exhibit 154: Merck and Co. Inc. - Business segments
  • Exhibit 155: Merck and Co. Inc. - Key news
  • Exhibit 156: Merck and Co. Inc. - Key offerings
  • Exhibit 157: Merck and Co. Inc. - Segment focus
  • 12.13 Novartis AG
  • Exhibit 158: Novartis AG - Overview
  • Exhibit 159: Novartis AG - Business segments
  • Exhibit 160: Novartis AG - Key offerings
  • Exhibit 161: Novartis AG - Segment focus
  • 12.14 Otsuka Holdings Co. Ltd.
  • Exhibit 162: Otsuka Holdings Co. Ltd. - Overview
  • Exhibit 163: Otsuka Holdings Co. Ltd. - Business segments
  • Exhibit 164: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibit 165: Otsuka Holdings Co. Ltd. - Segment focus
  • 12.15 Supernus Pharmaceuticals Inc.
  • Exhibit 166: Supernus Pharmaceuticals Inc. - Overview
  • Exhibit 167: Supernus Pharmaceuticals Inc. - Product / Service
  • Exhibit 168: Supernus Pharmaceuticals Inc. - Key offerings
  • 12.16 Teva Pharmaceutical Industries Ltd.
  • Exhibit 169: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 170: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.17 UCB SA
  • Exhibit 174: UCB SA - Overview
  • Exhibit 175: UCB SA - Product / Service
  • Exhibit 176: UCB SA - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 177: Inclusions checklist
  • Exhibit 178: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 179: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 180: Research methodology
  • Exhibit 181: Validation techniques employed for market sizing
  • Exhibit 182: Information sources
  • 13.5 List of abbreviations
  • Exhibit 183: List of abbreviations